ISPOR - Cost-Utility of First-Line Adalimumab and Tocilizumab Monotherapies in Rheumatoid Arthritis Based on Head-To-Head Data

Full Text

Cost-Utility of First-Line Adalimumab and Tocilizumab Monotherapies in Rheumatoid Arthritis Based on Head-To-Head Data

Abstract

Authors

E.J. Soini T. Hallinen V. Vihervaara M.J. Kauppi

Back to Volume 16, Issue 7

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now